Latest News and Press Releases

BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

BASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing...

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid...

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in...

Expanded alliance combines Lisata’s drug development expertise with GATC’s AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug...

BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending...

BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...